Segment and Geographic Information

9 Months Ended

Sep. 30, 2017

The Company manages its business and operations as one segment and is focused on advancing the treatment of acute and intensive care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company allocates resources and assesses financial performance on a consolidated basis. Revenues reported below are derived primarily from sales of Angiomax in the United States, including royalty revenue from Sandoz.

The geographic segment information provided below is classified based on the major geographic regions in which the Company operates. Long-lived assets are comprised of the Company’s noncurrent assets.



	Three Months Ended September 30,								Nine Months Ended September 30,
	2017				2016				2017				2016
	($ in thousands)
Net revenues:
United States	$	15,460	91.6	%	$	35,662	94.8	%	$	55,062	92.0	%	$	133,273	93.3	%
Europe	1,208		7.2	%	1,726		4.6	%	4,355		7.3	%	7,544		5.3	%
Rest of world	203		1.2	%	211		0.6	%	412		0.7	%	1,819		1.4	%
Total net revenues	$	16,871	100	%	$	37,599	100.0	%	$	59,829	100.0	%	$	142,636	100.0	%



	September 30, 2017				December 31, 2016
	($ in thousands)
Long-lived assets:
United States	$	708,309	99.9	%	$	1,047,098	99.6	%
Europe	833		0.1	%	4,160		0.4	%
Total long-lived assets	$	709,142	100.0	%	$	1,051,258	100.0	%